Investment advice: We believe that the gradual recovery of the macroeconomy and downstream industry, as well as the growing high-end film market, will bring new opportunities for the company's development. I am optimistic about the positive effects of the company's fixed growth project on the company's future development, and the broad development space of the company's big health strategy in the future. The company's EPS for 2016, 2017, and 2018 is estimated to be 0.18 yuan, 0.31 yuan, and 0.42 yuan, respectively, corresponding to the current estimated price-earnings ratio of 106 times, 63 times, and 46 times. Covered for the first time, with a “Recommended” rating. Risk warning: (1) macroeconomic downturn, downstream demand is insufficient; (2) the development of the big health strategy falls short of expectations; (3) sales of high-end functional films fall short of expectations.
【平安证券】金明精机:寒冰渐融江水暖,工业4.0和大健康战略值得看好
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.